NEW YORK (360Dx) – Hologic announced after the close of the market on Tuesday that it has completed the sale of its stake in blood screening firm Grifols for $1.85 billion.

At the time the deal was announced in December, Hologic Chairman, President, and CEO Steve MacMillan said that Grifols, while having excellent value for a non-core business, nonetheless, "was a drag on our growth" and operated in a challenging market with ongoing headwinds.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.